Page 1
Page 1
Enhancing the Dissolution Rate of Atorvastatin by Solid Dispersion Technique
In the last few decades, solid dispersion (SD) technology had been studied as an approach to produce an amorphous carrier to enhance the solubility, dissolution rate, and bioavailability of poorly water-soluble drugs. The use of suitable carrier and methodology in the preparation of SDs play a significant role in the biological behavior of the SDs. Atorvastatin is a statin group HMG-CoA reductase inhibitor drug that is commonly used to adverse cardiovascular events and to lower blood total cholesterol and LDL-cholesterol. the solubility of atorvastatin in water is very low (0.1 mg mL− 1), which results in reduced bioavailability. In order to enhance its solubility, we have prepared solid dispersions (SDs) of atorvastatin at different drug: polymer ratios (1:2, 1:10, 1:20,1:25 and 1:40), using polyethylene glycol 6000 as polymer and different preparation methods (co-precipitate and melting methods) The characterization of the SDs was performed using differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) The solubility of AT was improved by the incorporation PEG6000.
Alzheimers Disease
Alzheimer’s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors).
